Entropic Communications, Inc. - Common Stock ENTR 深 沪
已收盘 08-28 16:00:00 美东时间
15.31
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.31
- 总市值 8420.50万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.7068
- 委 比 0.00%
- 总股本 550.00万
- 历史最高 23.8849
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.6319
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics has received EU authorization to initiate the ELEVATE-45-201 Phase 1/2 clinical trial for ENTR-601-45, targeting Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. The global study will assess safety, tolerability, and efficacy, with plans to begin in Q3 2025.EN
05-28 11:00
NuScale (SMR) Stock Surges 21% After Smashing Q1 Revenue Estimates
NuScale Power shares surged 21% on Tuesday. The stock is up following the release of its Q1 earnings after Monday's close.
05-13 23:50
NuScale Power Reports Q1 Results: Details
Here's a look at the details from NuScale Power's first-quarter earnings report.
05-13 04:47
Trolli® Launches New Sour Brite Squad™ to Level Up Everyone's Candy Game Nationwide
Trolli unlocks three new crawler shapes in trending flavor combinations with its latest candy launch CHICAGO, May 6, 2025 /PRNewswire/ -- Trolli®, the rule-bending sour gummi brand known for...
05-06 21:00
WARNER MUSIC GROUP PARTNERS WITH ENTREPRENEURIAL POWERHOUSE ANJULA ACHARIA
'5 Junction' imprint focused on breaking American artists of South Asian heritage and talent from the Subcontinent in the U.S. NEW YORK, April 22, 2025 /PRNewswire/ -- Warner Music Group (Na...
04-22 23:00
Entrada Receives Authorization From UK MHRA And Research Ethics Committee To Initiate ELEVATE-45-201
ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients
03-24 19:22
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.
02-24 23:03
唯一持股Space X，这只ETF被美国散户爆买
ERShares自12月购入SpaceX股票以来，已吸引超过1.2亿美元资金流入，创下该基金7年来最佳资金流入纪录。SpaceX目前是该ETF的第一大持仓，占比8.1%。该基金创始人表示，“SpaceX是我们长期持有的股票。 我们不会改变这一点，可能会增加持股”。
01-25 20:09
89bio provides business update and outlook for 2025
89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, on Monday provided a corporate update and business outlook for 2025. The company completed enrollment in Phase 3 ENTRUST trial in patie...
01-13 21:36
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $1...
2024-11-01 04:01
